TC
OVID icon

Truvestments Capital’s Ovid Therapeutics OVID Stock Holding History

Truvestments Capital’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.56K Buy
+1,325
New +$3.42K ﹤0.01% 950

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Truvestments Capital's OVID Position: Q2 2026 in Review

Truvestments Capital opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 1,325 shares worth $3.56K. The stake represents ﹤0.01% of the portfolio and ranks #950 among its holdings.

131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Truvestments Capital held 1,325 shares of Ovid Therapeutics worth $3.56K as of Q2 2026.
  • Ovid Therapeutics was a new Truvestments Capital position in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #950 holding.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.